Preventing blood clots during first chemotherapy for germ cell tumors
Part of Cancer clinical trials.
This Phase 3 study tests whether giving enoxaparin (a blood thinner) can prevent dangerous blood clots in people with advanced germ cell tumors starting their first chemotherapy. It is especially focused on people who are at higher risk of clots.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and have a germ cell tumor with “good” or “intermediate” outlook
- Your cancer team thinks you can safely start first-line cisplatin-based chemotherapy
- You have not had any prior chemotherapy drugs that affect the whole body
- You must be able to sign consent and attend study visits and procedures
- You must have the required health coverage through the social security system
- If you are assigned to the clot-risk group: you may need blood test, body size, or lymph node size details showing higher clot risk
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if daily aspirin can prevent dangerous blood clots in people receiving chemotherapy for advanced testicular or germ cell cancer. It is for those at high risk of clots and aims to improve safety during treatment.
This Phase 3 trial compares a faster chemotherapy approach versus the standard schedule for people with intermediate- or poor-risk metastatic germ cell tumors. The goal is to see which schedule works better and is safer enough to use as initial treatment.
This study looks at how to manage germ cell tumors in children and young adults using careful monitoring for some patients and chemotherapy for others. It aims to see whether these approaches can control the cancer while avoiding unnecessary treatment when possible.
This phase 2 study looks at whether taking oral etoposide after high-dose chemotherapy helps people with a certain type of testicular or ovarian cancer avoid relapse. If you qualify, you may be assigned to take the medicine or simply be monitored without additional treatment.
This trial tests a second-line high-dose chemotherapy for germ cell tumors that have come back after initial treatment. It may be an option for patients whose cancer progressed after 3–4 cycles of standard platinum-based chemo.
This trial tests a maintenance therapy combining zanzalintinib and etoposide after you've completed high-dose chemotherapy and a stem cell transplant for germ cell cancer. The goal is to see if this drug combination helps prevent the cancer from coming back.
Hear when a new Germ Cell Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.